"Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis (PsA) through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. German Society of Rheumatology, (DGRh) 2017, Stuttgart, Germany, September 2017." by S Hall

Presentation

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis (PsA) through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. German Society of Rheumatology, (DGRh) 2017, Stuttgart, Germany, September 2017.

German Society of Rheumatology, (DGRh) (2017)

S Hall
Philip Mease, Providence St. Joseph Health
et.al.

Link

Disciplines

Rheumatology

Publication Date

September, 2017

Citation Information

S Hall, Philip Mease and et.al.. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis (PsA) through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. German Society of Rheumatology, (DGRh) 2017, Stuttgart, Germany, September 2017." German Society of Rheumatology, (DGRh) (2017)
Available at: http://works.bepress.com/philip-mease/224/